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Abstract
Background: The importance of individual microRNAs (miRNAs) in tumor has been established in different cancers.
However, their association with tumor chemoresistance has not been fully understood. Previously, we found two
novel MDR-associated microRNAs (miRNAs). In this report, we investigated the combined effects of miRNA gene
cluster in chemoresistance of breast cancer.
Methods: This study was performed in two different breast cancer cell lines (MCF-7 and MCF-7/ADR). The levels of
miRNAs and mRNA expression were determined by using Quantitative Real-Time PCR. Western blotting was used to
detect the levels of protein molecules. Cell viability was assessed by MTS assay. Bioinformatics and Luciferase
reporter assay was performed to examine miRNA binding to the 3′-UTR of target genes.
Results: The miR-302S family including miR-302a, miR-302b, miR-302c, and miR-302d was significantly down-regulated
in P-glycoprotein (P-gp)-overexpressing MCF-7/ADR cells. Overexpression of miR-302 increased intracellular
accumulation of ADR and sensitized breast cancer cells to ADR. Most importantly, miR-302S produced stronger
effects than each individual member alone. The four miRNAs cooperatively downregulate P-gp expression in
regulating drug sensitivity. However, our results showed that the suppression of P-gp expression by miR-302 is
not through typical miRNA-mediated mRNA degradation but at the level of protein and transcription. Further
studies identified MAP/ERK kinase kinase 1 (MEKK1) as a direct and functional target of miR-302. miR-302 showed
combinatorial effects on MKEE1 repression and MEKK1-mediated ERK pathway. The suppression of P-gp by miR-
302 was reversed by MEKK1 overexpression.
Conclusion: Our results indicate that miR-302 cooperatively sensitizes breast cancer cells to adriamycin via
suppressing P-glycoprotein by targeting MEKK1 of ERK pathway. miR-302 gene cluster may be a potential target
for reversing P-gp-mediated chemoresistance in breast cancer.
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Background
Breast cancer is the most common malignant tumor in
women [1]. Despite advances in diagnosis and treatment
approaches, the mortality due to breast cancer still re-
mains very high. This is attributable to the fact that can-
cer cells are able to develop mechanisms of resistance to
the therapeutic treatment, a process known as chemore-
sistance, which continues to be a major clinical obstacle
to the successful treatment of cancer [2, 3]. It may be
caused by drug efflux by transporters, inactivation by de-
toxification enzymes, the altered expression of pro-
antiapoptotic proteins, changes in tumor suppressor
gene expression, or the increased activity of DNA repair
mechanisms [4–6]. Recent evidence has demonstrated
that microRNAs (miRNAs) take part in these processes.
miRNAs is a type of endogenous non-coding RNA
(ncRNA). They modulate protein expression by promot-
ing RNA degradation and inhibiting transcription after
binding to the 3′-untranslated region (3′-UTR) of
mRNA [7]. Accumulating evidence has demonstrated
that miRNAs are responsible for post-transcriptional
regulation and participate in nearly all biological pro-
cesses [8]. miRNAs play an important role in tumorigen-
esis, with some able to act as oncogenes, others as
tumor suppressors and others displaying either onco-
genic or tumor-suppressive activities, depending on the
tissue and tumor context [9, 10]. They have recently
emerged as diagnostic and prognostic markers for suc-
cessful therapeutic responses. Recent investigations have
revealed that miRNAs are involved in the development
of drug resistance, for example, miR-520 h directly af-
fects cell chemosensitivity in breast cancer cells [11].
miR-130a plays a role in chemosensitivity in prostate
[12] and ovarian cancer [13], and the expression of miR-
124 is associated with chemosensitivity in tongue squa-
mous cell carcinoma(TSCC) patients [14].
Bearing in mind that the 3′ UTR of a single gene is
frequently targeted by several different miRNAs, and
that any one given miRNA can have several targets,
some belonging to the same functional network or sig-
naling pathway. A coordinated action of miRNAs on
their targets was proposed. For example, for the known
targets of miR-375, a combined addition of miR-124 and
let-7b led to a synergy in target inhibition [15]. Similarly,
the expression of miR-16, miR-34a and miR-106b altered
the cell cycle. Combining these miRNAs resulted in cell
cycle arrest that was stronger than for each of the miR-
NAs alone [16]. The regulation of the tumor suppressor
FUS1 in cancer cells depends on the presence of at least
three miRNAs (miR-93, miR-98,miR-197 and additional
unidentified miRNAs) [17]. To date, the specific miR-
NAs involved in the cooperatively regulating drug resist-
ance have yet to be characterized. In our previous study,
we performed miRNA microarray analysis to investigate
the differential miRNA expression profiling in parental
MCF-7 cells and its derivative mitoxantrone(MX)-resist-
ant MCF-7/MX cells. We found that miR-302S family in-
cluding miR-302a, miR-302b, miR-302c, and miR-302d
was significantly downregulated in MCF-7/MX cells. We
also found that miR-302 inhibit BCRP-mediated MX re-
sistance in vitro and in vivo study [18]. However, the in-
volvement of miR-302S in the development of other drug
resistance usually used in breast cancer therapy is unclear.
In this study, a multiple-drug resistant cell line, MCF-7/
Adriamycin (ADR), was derived from MCF-7 cells by ex-
posing them to gradually increasing concentrations of
adriamycin (ADR). We experimentally demonstrated that
miR-302 cluster, including miR-302a, miR-302b, miR-302c
and miR-302d exert a combinatorial effect on the reverse
the drug resistance of breast cancer cells. The four miR-
NAs cooperatively downregulate P-glycoprotein (P-gp)ex-
pression in regulating drug sensitivity. However, our
results showed that the suppression of P-gp expression by
miR-302a, miR-302b, miR-302c and miR-302d is not
through typical miRNA-mediated mRNA degradation but
at the level of protein and transcription. Further, we dem-
onstrate that the four miRNAs directly bind to and down-
regulate levels of MAP/ERK kinase kinase 1 (MEKK1), a
member of the MAPK Kinase (MAP2K) Kinase (MAP3K)
family. In cancer cells, miR-302S showed combinatorial ef-
fects on MEKK1 repression and MEKK1-mediated ERK
pathway. Importantly, the suppression of P-gp by miR-302
was reversed by MEKK1 overexpression, suggesting that
miR-302 cooperatively sensitizes breast cancer cells to
adriamycin via suppressing P-gp by targeting MEKK1 of
ERK pathway. Altogether, our results identify four specific
miRNAs that regulate drug sensitivity and indicated the
combination of miRNAs is required as an effective thera-
peutic strategy, and further elucidated the functional sig-
nificance of the four miRNA combination.
Methods
Cell lines
The human breast cancer MCF-7 cell line was pur-
chased from the American Type Culture Collection. The
adriamycin (ADR)-resistant MCF-7 cells (MCF-7/ADR)
were derived from the human breast cancer cell line
MCF-7, was maintained in the presence of 1 μM adria-
mycin. A series of MCF-7 cells with incremental resist-
ance to adriamycin were established by doxorubicin
challenge at the starting concentration of 1 nM. After
cells were tolerable, a double concentration of adriamy-
cin was applied. The process was repeatedly performed
to increase cell tolerance to adriamycin. The resulting
12th generations, MCF-7/ADR were cultured in DMEM
(Invitrogen, Carlsbad, CA) supplemented with 10 % FCS
and were added with the indicated adriamycin concen-
trations for resistance maintenance.
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Cell transfection
MCF-7 and MCF-7/ADR cells were transfected with 20
nM miR-302a, miR-302b, miR-302c, miR-302d, and
miR-302S (miR-302a-d) mimics or negative control miR-
NAs (NC) using Lipofectamine 2000, according to the
manufacturer’s instruction. After transfection for 48 h,
cells were used for Western blot and qRT-PCR.
MTS assay for proliferation activity
MCF-7 and MCF-7/ADR cells were seeded onto 96-well
plates at a density of 1,000 cells/well. After culture for
24 h, cells were transfected with 20 nM miR-302 mimics
for 24 h. Then, cells were treated with serial dilutions of
drugs for 48 h, followed by treatment with MTS (5 mg/
ml, Promega, WI, USA) for 2 h. The absorbance at
490 nm was measured using a multi-mode reader (LD942,
Beijing, China). The IC50 (50 % inhibitory concentration)
value, which represents the concentration of the drug that
demonstrates 50 % of cell growth inhibition, was calcu-
lated by normal probability transforms according to the
relationship of drug concentration and inhibition rate.
The probit regression models of SPSS 16.0 software were
used for computation.
Quantitative reverse transcription-PCR
Quantitative reverse transcription-PCR (qRT-PCR) was
performed to detect the relative expression of mRNA.
Briefly, total RNA was isolated from MCF-7 or MCF-7/
ADR cells using Trizol reagents (Invitrogen, CA, USA)
according to the manufacture’s protocol. RNA was re-
verse transcribed into complementary DNA using M-
MLV reverse transcriptase (Promega, WI, USA). RT-
PCR was performed using SYBR Premix Ex Taq™ II kit
(Takara, Dalian, China) in a final volume of 10 μl mix-
ture containing 1 μl cDNA, 0.5 μl of each primer, and
5 μl SYBRGreen. The reaction condition was as follows:
37 °C, 15 min, 85 °C, 5 s; 95 °C 5 min, followed by 95 °
C, 10 s, 56 °C, 45 s and 72 °C, 20 s for 45 cycles of amp-
lification. Relative mRNA expression was normalized to
GAPDH expression.
Luciferase report gene detection
The human P-gp 3′-UTR (380 bp) or MEKK1 3′-UTR
(2472 bp) was cloned into the XbaI site of the pGL3 vector
(Promega, WI, USA). Mutations in the miRNA-binding
site were generated using RCR-based mutagenesis (Takara,
Dalian, China). Luciferase reporter vectors (control), or
vectors containing wild type (pGL3- P-gp -3′UTR-Full or
pGL3- MEKK1 -3′UTR-Full) or mutated (pGL3-MEKK1-
3′UTR-Mut) 3′-UTRs of MEKK1 mRNA were co-
transfected into HEK-293T cells with miR-302a, miR-302b,
miR-302c, miR-302d, or miR-302S mimics, using Lipofec-
tamine 2000. After 24 h, luciferase activity was detected
using the Dual Luciferase Reporter Gene Assay kit
(Promega, WI, USA). Relative luciferase activity normal-
ized to the negative control was used for comparison
among groups.
Western blotting
MCF-7 or MCF-7/ADR cells were washed with ice-cold
PBS for 2 times, added RIPA lysis buffer, lysed on ice for
30 min, scrapped off, transferred into EP tube and centri-
fuged at 4 °C, 12,000 × g for 30 min. The supernatants
were collected and protein concentration was determined
using BCA protein quantitation kit. Each sample with
60 μg protein was added 1× SDS sample buffer
[100 mmol/L Tri-HCl (pH 6.8), 4 % SDS, 0.2 % bromophe-
nol blue, 20 % glycerol, 200 mmol/L β-mercaptoethanol],
and denatured at 95 °C for 5 min. Proteins were sepa-
rated by 10 % SDS-PAGE electrophoresis and trans-
ferred to 0.45 μm NC membrane. Membrane was
blocked with 5 % skim milk for 1 h, and incubated with
monoclonal antibodies (1:1,000 to 1:2,000 dilution) at
4 °C overnight. The membrane was then incubated with
horseradish peroxidase-linked goat anti-rabbit second-
ary antibodies (Santa cruz, CA, USA) at room
temperature for 1 h, washed with PBST three times,
and detected with a chemiluminescent detecting system
(Amersham, Freiburg, Germany).
ADR accumulation assay
ADR accumulation assay was performed as described
previously [19] with modifications. Briefly, cells were ex-
posed with 5 μM ADR for 2 h at 37 °C in the darkness.
The ADR accumulation was stopped by addition of ice-
cold phosphate-buffered saline (PBS). The intracellular
ADR level was determined by measuring ADR fluores-
cence using a flow cytometer (Becton–Dickinson).
RNA degradation analysis
48 h after MCF-7/ADR cells were transfected with 20
nM miR-302 mimics, actinomycin D (Sigma, CA, USA)
was added to a final concentration of 5 mg/mL to block
de novo RNA synthesis. Cells were harvested at 0, 2, 4,
6, and 8 h following actinomycin D treatment. P-gp or
MEKK1 mRNA levels were determined by qRT-PCR,
and normalized to GAPDH mRNA levels. All treatments
were conducted in triplicate.
Statistical analysis
Data were analyzed using the SPSS statistics 16.0 soft-
ware package. Results are presented as mean ± stand-
ard deviation (SD). One-way ANOVA was used to
compare differences among groups, followed by LSD
post-hoc tests. The P values < 0.05 were considered
statistically significant.
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Results
miR-302a/b/c/d is downregulated in MCF-7/ADR cells
overexpressing P-gp
To better understand the biological mechanisms of che-
moresistance in breast cancer cells and search for the re-
version opportunities, we selected adriamycin sensitive
and derived resistant breast cancer cell line pair(MCF-7
and MCF-7/ADR). To identify the differential sensitivity
of the parental MCF-7 and MCF-7/ ADR breast cancer
cell line to chemodrugs, we first determined the cytotox-
icity of chemotherapeutic drugs, including adriamycin
(ADR), paclitaxel(PAC) and etoposide(VP-16) by MTS
assay, all of which are currently used for the treatment
of breast cancer. As shown in Fig. 1a, MCF-7/ADR cells
showed resistance to ADR, PAC and VP-16 with higher
IC50 values (ADR:47.2 ± 4.33 μM, PAC:112.5 ± 10.16nM,
VP-16: 1.072 ± 0.099 mM) than MCF-7 cells(ADR:1.02 ±
0.09 μM, PAC:3.57 ± 0.35nM, VP-16:75.7 ± 4.65 μM).
The results showed that MCF-7/ADR cells had cross-
resistance ADR, PAC and VP-16. We then characterized
the differential expression of MDR-related ABC trans-
porters, including MRP, P-gp, LRP, and BCRP, between
the parental MCF-7 and its derivative ADR-resistant
MCF-7/ADR breast cancer cells, using Western blot. As
shown in Fig. 1b, the results showed that the MCF-7/
ADR cell line displayed obviously increased levels of P-
gp expression compared with the parental MCF-7 cell
line, while the other three detected MDR proteins only
showed slight upregulation in the MCF-7/ADR cell line.
These data suggest that the overexpression of P-gp is
one of the reasons that MCF-7/ ADR breast cancer cells
are resistant to chemodrugs. Figure 1c shows that miR-
302 members (302a, 302b, 302c, and 302d) share a high
sequence homology, differing only in the 3′ hexanucleo-
tides. We further examined the miR-302 in MCF-7 and
MCF-7/ADR cells. qRT-PCR results showed that miR-
302a, miR-302b, miR-302c and miR-302d were signifi-
cantly downregulated in MCF-7/ADR cells compared
with MCF-7 cells (Fig. 1d, P < 0.05).
miR-302 overexpression sensitizes MCF-7 and MCF-7/ADR
cells to ADR
To investigate the association of miR-302 expression
with breast cancer chemoresistance, we determined the
sensitivity of MCF-7 and MCF-7/ADR cells to ADR,
PAC and VP-16 after treatment with miR-302a, miR-
Fig. 1 Downregulation of miR-302 expressions in MCF-7/ADR cells. a Cells were treated with various concentrations of ADR, PAC or VP-16. Survived
cells were measured by MTS assay. MTS assay shows that MCF-7/ADR cells are much more resistant to ADR, PAC and VP-16 than MCF-7 cells (b) Left:
Western blotting analysis showing the protein expression of MRP, P-gp, LRP, and BCRP in MCF-7 and MCF-7/ADR cells. GAPDH was used as an internal
loading control. Right: Densitometric analysis for the detected protein expression. c Sequence alignment of human miR-302 family miRNAs. d qRT-PCR
indicates a significant down-regulation of miR-302 in MCF-7/ADR cells compared with MCF-7 cells. All graphs show means ± S.D. of three
independent experiments
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302b, miR-302c, miR-302d, and miR-302S mimics. The
expression level of miR-302 was confirmed by qRT-PCR,
showing that MCF-7 and MCF-7/ADR cells transfected
with miR-302 mimics had higher miR-302 expression
compared with those transfected with negative controls
(Fig. 2a). miR-302 mimics alone had no significant ef-
fects on proliferation in MCF-7 and MCF-7/ADR cells
(Fig. 2b). Following transfection of miR-302 mimics into
MCF-7 and MCF-7/ADR, we treated the cells with a
series of concentrations of ADR, PAC and VP-16. The in-
hibition of cell proliferation by the chemotherapeutic
drugs was significantly increased by overexpression of
miR-302a, miR-302b, miR-302d, and miR-302d in MCF-7
and MCF-7/ADR (Fig. 2b), suggesting that miR-302
sensitized MCF-7 and MCF-7/ADR cells to ADR, PAC
and VP-16 cytotoxicity. Coexpression of miR-302a, miR-
302b, miR-302c and miR-302d mimics combination (ie,
four miRNA combination) had a stronger effect on redu-
cing the cell growth compared with individual mimic
(Fig. 2b).
miR-302 increased ADR accumulation in MCF-7 and MCF-
7/ADR cells
We also investigated the effect of miR-302a, miR-302b,
miR-302c and miR-302d on ADR accumulation in MCF-
7 and MCF-7/ADR cells. The intracellular ADR accumu-
lation was evaluated after 2 h incubation with ADR. As
shown in Fig. 3a and b, overexpression of miR-302a,
Fig. 2 miR-302 modulated the resistance of human breast cancer cells to chemotherapeutic drugs. a qRT-PCR showing the relative expression of
miR-302a/b/c/d in untreated MCF-7 and MCF-7/ADR cells (Blank), cells treated with miR-302a,b,c,d mimics (a final concentration of 20nM) or the
four miRNAs mimic combination (miR-302S,the miRNAs mixed with miR-302a, miR-302b, miR-302c and miR-302d mimics by same concentration
(4 × 5nM = 20nM) and negative controls (NC). b Following untransfection (Blank), transfection with either of the negative control RNA (NC) or
miR-302 mimic, cells were treated with various concentrations of ADR, PAC and VP-16 for 48 h, respectively. The effect of the miR-302 mimic on
the viability of MCF-7 cells and MCF-7/ADR in response to the three chemotherapeutic drugs was determined using the MTS assay. n = 3 (*P < 0.05
compared with the control group, #P < 0.05 compared with individual member)
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miR-302b, miR-302c, and miR-302d significantly in-
creased intracellular ADR accumulation in MCF-7 and
MCF-7/ADR cells compared with controls. miR-302S
treatment resulted in a significantly increase in intracel-
lular ADR accumulation in the MCF-7 and MCF-7/
ADR cells than each individual member alone.
MiR-302 inhibits P-gp expression more strongly than each
individual member in MCF-7 and MCF-7/ADR cell
Overexpression of the ATP-binding cassette transporter
(ABC transporter) proteins P-gp in the cell membrane is
known to promote active transport of ADR out of the
cells. These processes decrease intracellular drug con-
centrations, and lead to multidrug resistance (MDR) of
breast cancer cells. Therefore, expression levels of P-gp
proteins are considered a useful clinical indicator of tumor
cells’ drug sensitivity and patient prognosis [20]. Since we
observed that miR-302 increased intracellular ADR accu-
mulation, we sought to determine whether P-gp proteins
were involved in the miR-302 overexpression-induced ef-
fects on MCF-7 and MCF-7/ADR cells. To investigate
whether P-gp expression was regulated by miR-302, we
transfected miRNAs mimics into MCF-7 and MCF-7/
ADR cells and then evaluated P-gp expression levels. We
found that the mRNA and protein expression of P-gp was
significantly down-regulated in the miR-302a, miR-302b,
miR-302c and miR-302d transfected cells compared with
cells transfected with control miRNA. Further, combina-
tions of four mimics had significant effects on the mRNA
(Fig. 4a) and protein (Fig. 4b) level of P-gp compared with
individual miRNA .
To investigate whether or not the 3′UTR of P-gp carries
binding sites for the four miRNAs, we constructed a P-gp
3′UTR luciferase reporter vector, and co-transfected the
four mimics individual or combination with P-gp mRNA 3′
UTR reporter into HEK-293T cells. miR-302 had no signifi-
cant effects on luciferase activity compared with control
miRNA (Fig. 4c). We next tested whether or not the
miRNA mimics regulate degradation of P-gp mRNA. We
analyzed the stability of P-gp mRNA in MCF-7/ADR cells.
Cells transfected with miR-302b or miR-302c mimic, were
treated with vehicle or 5 μg/mL actinomycin D (to inhibit
denovo RNA synthesis), and qRT-PCR were performed
with primers amplifying P-gp mRNA. As shown in Fig. 4d,
the half-life of P-gp mRNA in cells was not altered when
miR-302 was overexpressed in MCF-7/ADR cells. These re-
sults suggest that miR-302b, miR-302c and miR-302S does
not enhance the degradation of P-gp mRNA, implying that
a mechanism other than direct mRNA degradation may be
involved in miR-302 mediated P-gp inhibition.
Fig. 3 MiR-302 increased ADR accumulation in MCF-7 and MCF-7/ADR cells. Fluorescence intensity of ADR was detected by flow cytometry (up
panel) and relative intensity of fluorescence (down panel) was analyzed at 48 h after transfection with miR-302 mimic or miR-NC followed by
treatment with ADR at a final concentration of 1 μM for MCF-7 and 50 μM for MCF-7/ADR for 2 h in MCF-7 (a) and MCF-7/ADR (b) breast cancer
cells.( *P < 0.05 vs NC. #P < 0.05 vs each individual member alone.) All graphs show means ± S.D. of three independent experiments
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MiR-302 members directly target the 3′-UTR of MEKK1
and significantly suppress luciferase activity cooperatively
Because our results showed that suppression of P-gp ex-
pression by miR-302a, miR-302b, miR-302c and miR-
302d is not through typical miRNA-mediated mRNA
degradation but at the level of protein and transcription,
we hypothesized that a miR-302 target gene may func-
tion as a regulator of P-gp. To elucidate the mechanisms
by which the miR-302a, miR-302b, miR-302c and miR-
302d regulates P-gp expression, we used mRNA target-
predicting algorithms (TargetScan, miRanda, and Targe-
tRank) based on the presence of binding sites in the 3′
UTR. Of these genes that overlapped among these algo-
rithms, we found that MAP/ERK kinase kinase 1
(MEKK1), was one of the targets of miR-302a, miR-
302b, miR-302c and miR-302d. Previous studies also
have shown that MEKK1 phosphorylates the MAPK c-
Jun amino-terminal kinase (JNK) [21], and activation of
the JNK pathway can upregulate P-gp expression [22].
Therefore, in the next study, we choose MEKK1 as our
target gene to study the mechanism of downregulated P-
gp by miR-302. The 3′-UTRs of MEKK1 mRNA con-
tained one putative miR-302 binding sites (Fig. 5a). The
minimum free energy between miR-302 and the putative
binding sites in the 3′-UTRs of MEKK1 mRNA sug-
gested that miR-302 may target MEKK1 via binding
these putative sites (Fig. 5b). To investigate whether
MEKK1 is a direct target of miR-302, we generated a
firefly luciferase reporter vector containing the MEKK1
3′UTR (Fig. 5a). The vector was transfected along with
Fig. 4 MiR-302 decreased P-gp mRNA and protein expression not through targeting the 3′-UTRs of P-gp in MCF-7 and MCF-7/ADR cells. a qRT-
PCR showing the mRNA expression of P-gp in MCF-7and MCF-7/ADR cells. b Western blot and densitometric analysis showing the protein
expression of P-gp in MCF-7 cell and MCF-7/ADR cell. c Dual-luciferase assays showing repression of wild-type UTR (ABCB1-3′UTR-FULL)
following transfection of miR-302 and individual mimics or negative control mimic (NC). d The stability assay of P-gp mRNA. MCF-7/ADR cells were
harvested at 0, 2, 4 and 6 h after treatment with 2 μg/ml actinomycin residual mRNAs was detected by qRT-PCR. All graphs show means ± S.D. of three
independent experiments
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miRNA mimics into HEK-293T cells. Compared with the
negative control, overexpression of each individual miR-
NAs significantly reduced luciferase activity by approxi-
mately 19 to 25 % (Fig. 5c). At the same dose, miR-302S
inhibited luciferase activity by approximately 32 %, which
was significantly more than each individual member alone
(P < 0.05, Fig. 5c). Further, we generated mutant MEKK1
luciferase constructs, carrying base pair changes in
miRNA putative binding site located at the MEKK1 3′
UTR (Fig. 5a). All four miRNA mimics were transfected
along with mutated MEKK1 vectors into HEK-293T cells
to test the binding ability of different miRNA combina-
tions. Mutation of the four miRNA-binding sequences re-
duced the ability of inhibiting luciferase activity by miR-
302 (Fig. 5d), suggesting that they directly bind to the 3′
UTR of MEKK1.
We further studied the effect of miR-302 and each
individual member on MEKK1 expression by overex-
pressing these miRNAs in MCF-7 and MCF-7/ADR
cells. MEKK1 mRNA levels were confirmed by quanti-
tative PCR analysis 48 h post-transfection. A signifi-
cant decrease in MEKK1 mRNA levels was found in
cells transfected with each individual miRNAs, com-
pared with controls (miR-NC). In contrast, when the
four miRNAs were transfected together, we observed
a more significant decrease in MEKK1mRNA levels
(P < 0.05, Fig. 6a), which is consistent with the find-
ings of the luciferase experiments described above.
Similarly, a 50 % reduction in MEKK1 protein levels
was observed when the four miRNAs were transfected
together, suggesting again that they act cooperatively
(Fig. 6b).
Fig. 5 miR-302a,b,c and d directly targeted the 3′UTR of MEKK1 mRNA with cooperative effects. a Validation of the miR-302 target site in the
3′UTR of MEKK1 mRNA. The putative miR-302 targeted sequence in the MEKK1 mRNA. b RNAhybrid predicts one binding site of miR-302 in the MEKK1
3'-UTRs. The binding energy was calculated c & d Dual-luciferase assays showing repression of wild-type UTR MEKK1-3′UTR-FULL (c) or mutant UTR
MEKK1-3′UTR-MUT (d) following transfection of miR-302 mimics or negative control mimic (NC). All graphs show means ± S.D. of three independent
experiments. (* P< 0.05 vs. NC;#P< 0.05 vs. Single)
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RNA degradation experiments were conducted to
assess if miR-302 affect MEKK1 mRNA stability. The
data showed that miR-302b and miR-302c accelerated
the decay of MEKK1 mRNA, compared with the con-
trol. The higher rate of mRNA decay caused by miR-
302S than individual was also found (Fig. 6c). The re-
sults suggest that mRNA degradation could be an im-
portant mechanism underlying miR-302-mediated
posttranscriptional regulation of MEKK1.
MiR-302 decreases MEKK1-mediated ERK MAP kinase sig-
naling pathway in MCF-7 and MCF-7/ADR cells
We found that miR-302 negatively regulates MEKK1 by
targeting the MEKK1 mRNA-3′UTR in MCF-7 and
MCF-7/ADR cells. In addition, MEKK1 can phosphoryl-
ate and activate ERK and JNK MAPK pathway. We then
sought to determine whether the MEKK1-mediated
downstream signal pathway was also impacted by miR-
302. Therefore, we examined changes in the expression
of proteins association with the MAPK pathway, includ-
ing p38, JNK and ERK in breast cancer cells following
miR-302 overexpression. The results showed that after
transfection with miR-302 mimics in MCF-7 and MCF-
7/ADR cells, the expression of phosphorylation levels of
ERK was decreased (Fig. 7a and b). Moreover, the four
miRNAs combination effects were notably higher than
those treated with individual miRNA. The total and
phosphorylated protein levels of JNK and p38 were
unaffected by miR-302 mimics transfection in any of
the cell types (Fig. 7a and b). These results indicated
that miR-302 may be an important regulator of ERK
signaling pathway.
MEKK1-mediated ERK pathway activation accounts for the
decreased P-gp expression induced by overexpression of
miR-302
In the previous experiments, we found that induced ex-
pression of miR-302 led to an increased drug sensitivity.
These changes appeared to be due to inhibition of P-gp
expression. ERK signaling pathway is known to cause ac-
tivation and expression of P-gp [23]. We also found that
miR-302 suppressed ERK pathway in breast cancer cells.
To further investigate whether inhibition of MEKK1-
mediated ERK pathways was involved in the miR-302 in-
duced P-gp suppression, MCF-7 and MCF-7/ADR cells
were co-transfected miR-302 mimics with MEKK1
cDNA(lacking the 3′UTR sequence) inducing expression
of MEKK1. The results showed that co-transfection of
pcDNA3.1(+)-MEKK1 and miR-302 mimics increased
MEKK1 expression (Fig. 8a and b). miR-302 suppressed
P-gp suppression and ERK pathway, which was reversed
by MEKK1 overexpression (Fig. 8a and b). These results
demonstrated that P-gp suppression by miR-302 is medi-
ated by down-regulation of MEKK1-mediated ERK path-
way. Collectively, these results indicate that the synergistic
overexpression of these four miRNAs sensitizes breast
cancer cells to ADR more effectively than individual
miRNA alone. This might be due in part to the
Fig. 6 The relative expressions of MEKK1mRNA and protein in MCF-7 and MCF-7/ADR cells after miRNA transfection. a qRT-PCR showing the mRNA
expression of MEKK1 in MCF-7and MCF-7/ADR cells. b Western blot and densitometric analysis showing the protein expression of MEKK1 in MCF-7 cell
and MCF-7/ADR cell. c The stability assay of MEKK1 mRNA. MCF-7/ADR cells were harvested at 0, 2, 4, 6 and 8 h after treatment with 5 mg/mL actinomycin
D. Residual mRNAs was detected by qRT-PCR. All graphs show means ± S.D. of three independent experiments. (* P < 0.05 vs. NC;#P < 0.05 vs. Single)
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Fig. 7 (See legend on next page.)
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indirectly suppressing P-gp by targeting MEKK1-
mediated ERK pathway.
Discussions
Although chemotherapy has greatly improved the prog-
nosis of breast cancer, drug-resistance still remains as
the main obstacle of successful treatment. Recently,
miRNAs were reported to be differentially expressed in
drug resistant cancers and could regulate the drug resist-
ance. In the present study, we found that miR-302 clus-
ter were differentially expressed between MCF-7/ADR
and MCF-7. In the transfection experiments, we found
alteration of miR-302 expression could change the de-
gree of ADR, PAC and VP-16 resistance in MCF-7 and
MCF-7/ADR. Previous studies showed that miR-302
cluster are highly expressed in embryonic stem cells
(ESCs) and induced pluripotent stem cells (iPSCs), and
their expression levels rapidly decline as pluripotent
stem cells begin to differentiate [24]. Recent studies have
shown that miR-302 targets epigenetic regulators
(AOF1/2, MECP1-p66, MECP2 and MBD2) [25], cell-
cycle regulators (Cyclin D1/D2, CDK2, BMI-1 and
PTEN [26]), TGF-β regulators (Lefty1/2 [27] and
TGFBR2 [28]), BMP inhibitors (DAZAP2, SLAIN1, and
TOB2) [29] and NR2F2 [30]. Most studies about the role
of miR-302 have been done in ESCs, but the function of
miR-302 in cancer has not been studied. Currently, a
few studies focused on the role of miR-302 in tumor,
Yang CM et al. found that expression of the miR-302/
367 cluster in glioblastoma cells suppresses tumorigenic
gene expression patterns and abolishes transformation
related phenotypes [31]. The results of the current study
provide the evidence to suggest that miR-302 play an
important role in drug sensitivity.
Furthermore, we also found that ectopic the miR-
302a/b/c/d combination expression sensitizes MCF-7/
ADR cells to ADR more efficiently than inducing an in-
dividual miRNA. This effect cannot be attributed to the
miRNA dose, since the same amount of total miRNA
was used irrespective of whether they were transfected
alone or in combination. We show that the combined
overexpression of miRNAs (miR-302a, miR-302b, miR-
302c and miR-302d) could potentially be used as a ther-
apy for breast cancer. However, additional animal and
human studies are warranted. Based this results, we
highlighted the importance of a combination of miRNAs
as a therapeutic target, a concept that could be used suc-
cessfully to promote sensitivity in other cancers.
Our study found the expression of P-gp levels in the
MCF-7/ADR was significantly higher than that in the
MCF-7, suggesting that over-expression of P-gp may be
one of mechanism of drug resistance formation in MCF-7/
ADR cells. P-gp is an ATP-dependent membrane pump
that transports the drug out of cells, resulting in multidrug
resistance. Therefore, inhibition of P-gp transporter func-
tion or inhibition of its expression may reverse the MDR
phenotype through enhancing intracellular accumulation of
anticancer drugs. There has been a worldwide effort investi-
gating chemical agents for their ability to overcome MDR
through interacting with P-gp and inhibiting its transporter
function. These MDR modulators include calcium channel
blockers [32], calmodulin inhibitors [33], and other classes
of compounds [34]. Recently, several miRNAs have been
identified as critical regulators of P-gp mediated drug resist-
ance in many cancer. For instance, miR-451 overcame the
doxorubicin resistance by downregulating P-gp expression
in the doxorubicin resistant breast cancer cell lines MCF-7/
ADR [35]. Inhibition of miR-27a enhanced the paclitaxel
sensitivity in A2780/Taxol by modulating MDR1/P-gp ex-
pression [36]. Inhibiting the expression of miR-130a re-
sulted in down-regulating of MDR1 mRNA and P-gp in
A2780/DDP ovarian cancer cell line [13]. In this study, we
proved that overexpression of miR-302 resulted in down-
regulating of MDR1 mRNA and P-gp. ADR accumulation
was also increased in miR-302 mimic-transfected MCF-7
and MCF-7/ADR cells. These results indicate that miR-302
reduces the efflux of cytotoxic drugs by downregulating the
expression of the ABC transporter P-gp.
However, bioinformatics analysis and luciferase re-
porter assay experiment showed no direct binding site of
miR-302 in MDR1 mRNA-3′UTR, How might P-gp ex-
pression be down-regulated by elevated miR-302? Here,
we identified MEKK1 as the functional target, through
which miR-302 regulates P-gp expression and chemore-
sistance. The interaction of miR-302 with the 3′UTR of
the MEKK1 mRNA was confirmed by the luciferase
assay, in which the luciferase activity of the reporter
gene harboring 3′UTR of MEKK1 mRNA was signifi-
cantly inhibited by miR-302. Furthermore, we found that
miR-302a, miR-302b, miR-302c and miR-302d mimics
inhibited the expression of MEKK1 in MCF-7 and MCF-
7/ADR cells, further suggesting that miR-302 specifically
down-regulated MEKK1. To directly demonstrate that
(See figure on previous page.)
Fig. 7 Overexpression of miR-302 decreased the expression of the ERK signal pathway. a MCF-7 and MCF-7/ADR cells were transfected with miR-302a,
miR-302b, miR-302c, miR-302d, miR-302S mimic, respectively. Total cellular proteins (50 μg) from exponentially growing cells treated as indicated in the
figure were subjected to western blot analysis with antibodies directed against the proteins or their phosphorylated form as indicated. GAPDH
was applied as control for equal loading. All experiments were carried three times independently. b Densitometric analysis for the detected
protein expression
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suppression of MEKK1 by miR-302 was responsible for
the decreased P-gp expression, we performed a rescue
experiment by expressing MEKK1 cDNA in MCF-7 and
MCF-7/ADR cells. Strikingly, expression of the MEKK1
rescued the down-regulatory effect of miR-302 on P-gp
in MCF-7/ADR cells. Thus, these results indicated a
Fig. 8 Overexpression of MEKK1 restored the inhibition of P-gP induced by miR-302. a Cells were co-transfected with miRNA mimics indicated in
the figure and MEKK1- cDNA(lacking the 3′UTR sequence ) for 48 h, then lysates were harvested and subjected to immunoblotting with anti-MEKK1,
anti-ERK, anti-p-ERK, and anti-P-gP antibodies. GAPDH was applied as control for equal loading. All experiments were carried three times independently.
b Densitometric analysis for the detected protein expression. (* P < 0.05 vs. NC)
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crucial requirement for MEKK1 in mediating miR-302-
induced down-regulation of P-gp.
MEKK1 is an upstream activator of p38, JNK and
ERK1/2 through its kinase domain [37]. Previous studies
have shown that activation of p38,JNK and ERK co-
operatively increase transport activity of P-gp and induce
a multidrug resistant phenotype [38], we showed in this
study that miR-302 decreased ERK activation in the
MCF-7 and MCF-7/ADR cells. It is therefore very likely
that miR-302 inhibited MEKK1 expression via binding
to the 3′ UTR of MEKK1 mRNA, which in turn de-
creased ERK activation, thereby leading to the repression
of MDR1 mRNA expression and ultimately the repres-
sion of P-gp protein expression.
Several studies have shown that different miRNAs can
cooperatively regulate the same target gene. For ex-
ample, Georges et al. reported that miR-192 and miR-
215 cooperatively regulated cell cycle transcripts [39].
Frampton et al. showed that miR-21, miR-23a, and miR-
27a cooperatively inhibited tumor suppressor genes to
promote pancreatic tumor growth and progression.
Kotani et al. found that miR-128b and miR-221 coopera-
tively sensitized MLL-AF4 acute lymphocytic leukemia
cells to glucocorticoids [40]. Our study showed that miR-
302S exhibited more strong effects on inhibition of P-gp
and MEKK1 expression than each individual member
alone, suggesting that miR-302 members cooperatively
inhibited P-gp and MEKK1 expression. Several studies
have shown that miRNAs reduce protein expression pre-
dominantly by destabilization of the target mRNA. In the
present study, we found that miR-302S accelerated the
decay of MEKK1 mRNA compared with miR-302b and
miR-302c, suggesting that miR-302 members may co-
operatively promote degradation of MEKK1 mRNA.
Conclusions
The results of this study demonstrate that miR-302 in-
creases the sensitivity of breast cancer cells to the antican-
cer agent ADR, PAC and VP-16 by downregulating P-gp
expression. Most importantly, we found that miR-302S
produced stronger effects than each individual member
alone, suggesting that miR-302 members may coopera-
tively downregulate P-gp expression to increase chemo-
sensitivity of breast cancer cells. Additionally, MEKK1
was confirmed as a functional target of miR-302 in
breast cancer cells, miR-302 sensitizes breast cancer
cells to chemodrugs via suppressing P-gp by targeting
MEKK1 of ERK pathway. These results enhance our
understanding of the molecular network underlying
MDR in breast cancer.
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